EXELIXIS INC (EXEL) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:EXEL • US30161Q1040

42.37 USD
-0.28 (-0.66%)
At close: Feb 5, 2026
42.37 USD
0 (0%)
After Hours: 2/5/2026, 8:22:42 PM
Fundamental Rating

8

We assign a fundamental rating of 8 out of 10 to EXEL. EXEL was compared to 524 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making EXEL a very profitable company, without any liquidiy or solvency issues. EXEL is growing strongly while it also seems undervalued. This is an interesting combination This makes EXEL very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • EXEL had positive earnings in the past year.
  • EXEL had a positive operating cash flow in the past year.
  • Each year in the past 5 years EXEL has been profitable.
  • EXEL had a positive operating cash flow in each of the past 5 years.
EXEL Yearly Net Income VS EBIT VS OCF VS FCFEXEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

  • EXEL has a better Return On Assets (24.01%) than 97.52% of its industry peers.
  • The Return On Equity of EXEL (31.37%) is better than 97.71% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 26.31%, EXEL belongs to the top of the industry, outperforming 98.86% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for EXEL is significantly below the industry average of 18.09%.
  • The 3 year average ROIC (10.78%) for EXEL is below the current ROIC(26.31%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 24.01%
ROE 31.37%
ROIC 26.31%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
EXEL Yearly ROA, ROE, ROICEXEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

  • EXEL's Profit Margin of 29.63% is amongst the best of the industry. EXEL outperforms 95.80% of its industry peers.
  • EXEL's Profit Margin has declined in the last couple of years.
  • The Operating Margin of EXEL (35.85%) is better than 97.71% of its industry peers.
  • In the last couple of years the Operating Margin of EXEL has declined.
  • With an excellent Gross Margin value of 96.63%, EXEL belongs to the best of the industry, outperforming 96.56% of the companies in the same industry.
  • In the last couple of years the Gross Margin of EXEL has remained more or less at the same level.
Industry RankSector Rank
OM 35.85%
PM (TTM) 29.63%
GM 96.63%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
EXEL Yearly Profit, Operating, Gross MarginsEXEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), EXEL is creating value.
  • EXEL has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for EXEL has been reduced compared to 5 years ago.
  • There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EXEL Yearly Shares OutstandingEXEL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EXEL Yearly Total Debt VS Total AssetsEXEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 12.50 indicates that EXEL is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of EXEL (12.50) is better than 84.54% of its industry peers.
  • There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 12.5
ROIC/WACC2.95
WACC8.93%
EXEL Yearly LT Debt VS Equity VS FCFEXEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 3.75 indicates that EXEL has no problem at all paying its short term obligations.
  • EXEL's Current ratio of 3.75 is in line compared to the rest of the industry. EXEL outperforms 45.42% of its industry peers.
  • A Quick Ratio of 3.68 indicates that EXEL has no problem at all paying its short term obligations.
  • The Quick ratio of EXEL (3.68) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.75
Quick Ratio 3.68
EXEL Yearly Current Assets VS Current LiabilitesEXEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.51%, which is quite impressive.
  • The Earnings Per Share has been growing by 12.65% on average over the past years. This is quite good.
  • The Revenue has grown by 9.93% in the past year. This is quite good.
  • Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 17.51% on average per year.
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%

3.2 Future

  • Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 25.68% on average per year.
  • Based on estimates for the next years, EXEL will show a quite strong growth in Revenue. The Revenue will grow by 9.99% on average per year.
EPS Next Y46.91%
EPS Next 2Y32.4%
EPS Next 3Y30.29%
EPS Next 5Y25.68%
Revenue Next Year7.7%
Revenue Next 2Y9.84%
Revenue Next 3Y11.53%
Revenue Next 5Y9.99%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EXEL Yearly Revenue VS EstimatesEXEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
EXEL Yearly EPS VS EstimatesEXEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 17.88, the valuation of EXEL can be described as rather expensive.
  • Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 95.04% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 27.67. EXEL is valued slightly cheaper when compared to this.
  • EXEL is valuated correctly with a Price/Forward Earnings ratio of 13.07.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 96.95% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of EXEL to the average of the S&P500 Index (27.20), we can say EXEL is valued rather cheaply.
Industry RankSector Rank
PE 17.88
Fwd PE 13.07
EXEL Price Earnings VS Forward Price EarningsEXEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 96.76% of the companies in the same industry are more expensive than EXEL, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, EXEL is valued cheaply inside the industry as 97.14% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 14.57
EV/EBITDA 11.57
EXEL Per share dataEXEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of EXEL may justify a higher PE ratio.
  • A more expensive valuation may be justified as EXEL's earnings are expected to grow with 30.29% in the coming years.
PEG (NY)0.38
PEG (5Y)1.41
EPS Next 2Y32.4%
EPS Next 3Y30.29%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • EXEL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EXELIXIS INC

NASDAQ:EXEL (2/5/2026, 8:22:42 PM)

After market: 42.37 0 (0%)

42.37

-0.28 (-0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-10
Inst Owners97.46%
Inst Owner Change-2.28%
Ins Owners2.18%
Ins Owner Change4.47%
Market Cap11.36B
Revenue(TTM)2.29B
Net Income(TTM)677.90M
Analysts76.3
Price Target46.24 (9.13%)
Short Float %9.82%
Short Ratio10.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.63%
Min EPS beat(2)9.27%
Max EPS beat(2)13.99%
EPS beat(4)4
Avg EPS beat(4)20.73%
Min EPS beat(4)9.27%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)31.52%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)13
Avg EPS beat(16)41.2%
Revenue beat(2)0
Avg Revenue beat(2)-1.87%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.36%
Revenue beat(12)4
Avg Revenue beat(12)2.52%
Revenue beat(16)7
Avg Revenue beat(16)3.42%
PT rev (1m)0.12%
PT rev (3m)3.28%
EPS NQ rev (1m)8.63%
EPS NQ rev (3m)32.56%
EPS NY rev (1m)1.38%
EPS NY rev (3m)13.36%
Revenue NQ rev (1m)-0.69%
Revenue NQ rev (3m)-0.51%
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)0.46%
Valuation
Industry RankSector Rank
PE 17.88
Fwd PE 13.07
P/S 4.96
P/FCF 14.57
P/OCF 14.36
P/B 5.26
P/tB 5.42
EV/EBITDA 11.57
EPS(TTM)2.37
EY5.59%
EPS(NY)3.24
Fwd EY7.65%
FCF(TTM)2.91
FCFY6.86%
OCF(TTM)2.95
OCFY6.96%
SpS8.53
BVpS8.06
TBVpS7.82
PEG (NY)0.38
PEG (5Y)1.41
Graham Number20.73
Profitability
Industry RankSector Rank
ROA 24.01%
ROE 31.37%
ROCE 33.48%
ROIC 26.31%
ROICexc 44.11%
ROICexgc 46.12%
OM 35.85%
PM (TTM) 29.63%
GM 96.63%
FCFM 34.08%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 37.81%
Cap/Sales 0.49%
Interest Coverage 250
Cash Conversion 93.06%
Profit Quality 115.03%
Current Ratio 3.75
Quick Ratio 3.68
Altman-Z 12.5
F-Score8
WACC8.93%
ROIC/WACC2.95
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
EPS Next Y46.91%
EPS Next 2Y32.4%
EPS Next 3Y30.29%
EPS Next 5Y25.68%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
Revenue Next Year7.7%
Revenue Next 2Y9.84%
Revenue Next 3Y11.53%
Revenue Next 5Y9.99%
EBIT growth 1Y34.85%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year54.89%
EBIT Next 3Y25.82%
EBIT Next 5Y1.16%
FCF growth 1Y112.18%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y99.5%
OCF growth 3Y20.43%
OCF growth 5Y5.84%

EXELIXIS INC / EXEL FAQ

What is the fundamental rating for EXEL stock?

ChartMill assigns a fundamental rating of 8 / 10 to EXEL.


Can you provide the valuation status for EXELIXIS INC?

ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.


Can you provide the profitability details for EXELIXIS INC?

EXELIXIS INC (EXEL) has a profitability rating of 8 / 10.


Can you provide the financial health for EXEL stock?

The financial health rating of EXELIXIS INC (EXEL) is 9 / 10.


What is the expected EPS growth for EXELIXIS INC (EXEL) stock?

The Earnings per Share (EPS) of EXELIXIS INC (EXEL) is expected to grow by 46.91% in the next year.